Abemaciclib With Endocrine Therapy in the Treatment of High-Risk Early Breast Cancer: ASCO Optimal Adjuvant Chemotherapy and Targeted Therapy Guideline Rapid Recommendation Update

Optimal Adjuvant Chemotherapy and Targeted Therapy Guideline Expert Panel

Research output: Contribution to journalReview articlepeer-review

2 Scopus citations

Abstract

ASCO Rapid Recommendations Updates highlight revisions to select ASCO guideline recommendations as a response to the emergence of new and practice-changing data. The rapid updates are supported by an evidence review and follow the guideline development processes outlined in the ASCO Guideline Methodology Manual. The goal of these articles is to disseminate updated recommendations, in a timely manner, to better inform health practitioners and the public on the best available cancer care options.

Original languageEnglish (US)
Pages (from-to)307-309
Number of pages3
JournalJournal of clinical oncology : official journal of the American Society of Clinical Oncology
Volume40
Issue number3
DOIs
StatePublished - Jan 20 2022

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint

Dive into the research topics of 'Abemaciclib With Endocrine Therapy in the Treatment of High-Risk Early Breast Cancer: ASCO Optimal Adjuvant Chemotherapy and Targeted Therapy Guideline Rapid Recommendation Update'. Together they form a unique fingerprint.

Cite this